Biocon Limited
Axis Mutual Fund bought 6,26,000 shares of Biocon Limited for ₹25.04 Cr at ₹400.00 apiece in a block deal. This occurred as Mylan Inc. exited its entire 5.64% stake in Biocon through block deals.
A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.
Subsidiary of Axis Bank, India's third-largest private sector bank. Manages over Rs 3.5 lakh crore in AUM. Built its brand on a quality growth equity philosophy with concentrated high-conviction portfolios. Flagship Axis Flexi Cap and Axis Bluechip funds are widely held among retail investors and drove significant AUM growth through the 2017-2021 bull cycle.